Identification of hub genes and pathways in adrenocortical carcinoma by integrated bioinformatic analysis

Jinshuai Guo1, Yinzhong Gu2, Xiaoyu Ma1

  • 1Department of Predictive Medicine, Institute of Biomedical Informatics, Cell Signal Transduction Laboratory, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Henan University, Kaifeng, China.

Insights

Adrenocortical carcinoma (ACC) research identified key genes involved in cell division and growth. High expression of these genes correlates with poorer patient survival, offering potential new therapeutic targets for this rare cancer.

Area of Science:

  • Oncology
  • Genomics
  • Bioinformatics

Background:

  • Adrenocortical carcinoma (ACC) is a rare, aggressive cancer with limited treatment options.
  • Understanding ACC tumorigenesis is crucial for developing novel diagnostic and therapeutic strategies.

Purpose of the Study:

  • To identify differentially expressed genes (DEGs) and hub genes in ACC.
  • To explore molecular mechanisms and potential biomarkers for ACC treatment and diagnosis.

Main Methods:

  • Downloaded and analyzed three gene expression profiles (GSE10927, GSE12368, GSE90713) from the GEO database.
  • Utilized Limma for DEG analysis, DAVID for GO and KEGG enrichment, STRING and Cytoscape for PPI network construction, and GEPIA for hub gene validation.

Main Results:

  • Identified 74 up-regulated and 126 down-regulated DEGs in ACC.
  • Up-regulated DEGs are enriched in cell cycle and nuclear division pathways; down-regulated DEGs are linked to angiogenesis.
  • Nine hub genes (CCNB1, CDK1, TOP2A, CCNA2, CDKN3, MAD2L1, RACGAP1, BUB1, CCNB2) were identified, with high expression correlating to worse overall survival.

Conclusions:

  • The identified hub genes and enriched pathways are potentially involved in ACC tumorigenesis.
  • These findings offer new therapeutic targets and diagnostic opportunities for adrenocortical carcinoma.